MARKET

DMPI

DMPI

DelMar Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.3982
-0.0057
-1.41%
Closed 17:13 03/31 EDT
OPEN
0.4070
PREV CLOSE
0.4040
HIGH
0.4125
LOW
0.3830
VOLUME
200.51K
TURNOVER
--
52 WEEK HIGH
5.75
52 WEEK LOW
0.3800
MARKET CAP
4.54M
P/E (TTM)
-0.2087
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average DMPI stock price target is 3.000 with a high estimate of 4.000 and a low estimate of 2.000.

EPS

DMPI News

More
  • DelMar Pharmaceuticals Receives Nasdaq Bid Price Extension
  • PR Newswire · 5d ago
  • DelMar Pharmaceuticals [Nasdaq:DMPI] Reports Over 50% Enrollment in Phase 2 Clinical Trial of VAL-083 For Adjuvant Treatment of Brain Tumors
  • PR Newswire · 03/04 13:30
  • DelMar Pharma up 4% advancement of VAL-083 study
  • Seeking Alpha - Article · 02/19 17:24
  • DelMar Pharmaceuticals [Nasdaq:DMPI] Enrolls Final Patient in Phase 2 Clinical Trial of VAL-083 For First-Line Treatment of Brain Tumors
  • PR Newswire · 02/19 13:00

Industry

Holding Companies
+0.31%
Financials
-2.11%

Hot Stocks

Symbol
Price
%Change

About DMPI

DelMar Pharmaceuticals, Inc. is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer. VAL-083 is being evaluated in a Phase II clinical trial for the treatment of refractory GBM. In addition to its clinical development activities in the United States, the Company has obtained certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. Its drug discovery research focuses on identifying validated clinical and commercial-stage compounds, and establishing a scientific rationale for development in orphan drug indications. VAL-083 is an alkylating agent, which crosses the blood-brain-barrier (BBB).
More

Webull offers kinds of DelMar Pharmaceuticals Inc stock information, including NASDAQ:DMPI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DMPI stock news, and many more online research tools to help you make informed decisions.